Metastatic rectal cancer responding to third-line therapy employing bevacizumab after failure of oxaliplatin and irinotecan: Case report

Japanese Journal of Clinical Oncology

Volumn 38, Issue 7, 2008, Pages 493-496

  Shitara, Kohei ^a,b   Munakata, Masaki ^a   Muto, Osamu ^a   Sakata, Yuh ^a  

^a Misawa City Hospital   (Japan)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Bevacizumab; Colorectal cancer; Third line

Indexed keywords

AMLODIPINE; BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EPISTAXIS; FEASIBILITY STUDY; FEMALE; HUMAN; HYPERTENSION; LUNG METASTASIS; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MULTIPLE CYCLE TREATMENT; RECTUM ANTERIOR RESECTION; RECTUM CANCER; RECTUM SURGERY; STOMATITIS;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MIDDLE AGED; RECTAL NEOPLASMS; SALVAGE THERAPY;

EID: 48849100385     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyn046     Document Type: Article

References (14)

1. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350;2335-42.
2. Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial. J Clin Oncol 2005;23:3697-705.
3. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25:1539-44.
4. Meta-analysis Group in Cancer: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer. J Clin Oncol 2004;10:3766-75.
5. Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 2004;22:229-37.
6. Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004;23:1209-14.
7. ® Practice Guidelines in Oncology. Version 1.
8. Chen HY, Mooney M, Boron M, Vena D, Mosby K, Grochow L, et al. Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: An NCI Treatment Referral Center Trial TRC-0301. J Clin Oncol 2006;24:3354-60.
9. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001;7:2958-70.
10. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al, Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45.
11. Van Cutsem E, Nowacki M, Lang I, Cascinu S, Shehepotin I, Mantel J, et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial. J Clin Oncol 2007;25, June 20 Supplement. (Abstract 4000).
12. Eng C, Maurel J, Scheithauer W, Wong L, Lutz M, Middleton C, et al. Impact on quality of life of adding cetuximab to irinotecan in patients who have failed prior oxaliplatin-based therapy: The EPIC trial. J Clin Oncol. 2007;25, June 20 Supplement. (Abstract 4003).
13. Grothey A, Hedrick EE, Mass RD, Sarkar S, Suzuki S, Ramanathan RK, et al. Response-independent survival benefit in metastatic colorectal cancer: A comparative analysis of N9741 and AVF2107. J Clin Oncol 2008;26:183-9.
14. Saltz LB, Lenz HJ, Kindler HL, Hochster HS, Wadler S, Hoff PM, et al. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: The BOND-2 study. J Clin Oncol 2007;25:4557-61.